Arrowhead Pharmaceuticals Inc. (ARWR)

27.51
0.38 1.36
NASDAQ : Health Technology
Prev Close 27.89
Open 27.98
Day Low/High 27.29 / 28.19
52 Wk Low/High 10.41 / 27.97
Volume 1.92M
Avg Volume 1.97M
Exchange NASDAQ
Shares Outstanding 94.81M
Market Cap 2.51B
EPS -0.70
P/E Ratio 368.86
Div & Yield N.A. (N.A)
Arrowhead To Report Fiscal 2014 Fourth Quarter And Year End Financial Results

Arrowhead To Report Fiscal 2014 Fourth Quarter And Year End Financial Results

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it will report its financial results for the fiscal 2014 fourth quarter and year...

Arrowhead Files For Regulatory Permission To Begin Phase 1 Trial Of RNAi Therapeutic ARC-AAT

Arrowhead Files For Regulatory Permission To Begin Phase 1 Trial Of RNAi Therapeutic ARC-AAT

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it recently filed an application for approval to begin a Phase 1 clinical trial of...

ARWR January 2017 Options Begin Trading

ARWR January 2017 Options Begin Trading

Investors in Arrowhead Research Corp saw new options become available today, for the January 2017 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 795 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Arrowhead To Present At Upcoming Conferences

Arrowhead To Present At Upcoming Conferences

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that the Company will present at upcoming investor and scientific conferences.

Arrowhead Research Stock Sees Short Interest Make 10% Move

Arrowhead Research Stock Sees Short Interest Make 10% Move

The most recent short interest data has been released by the NASDAQ for the 10/31/2014 settlement date, which shows a 1,228,584 share increase in total short interest for Arrowhead Research Corp , to 13,404,343, an increase of 10.09% since 10/15/2014. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Arrowhead Presents Data On ARC-520 And ARC-AAT At AASLD The Liver Meeting® 2014

Arrowhead Presents Data On ARC-520 And ARC-AAT At AASLD The Liver Meeting® 2014

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that initial data from the ongoing Phase 2a study of ARC-520, its RNAi therapeutic...

Super Important Biotech and Drug Stock Events for November

Super Important Biotech and Drug Stock Events for November

A cheat sheet of earnings, medical meetings, FDA approval decisions and clinical trial results for healthcare investors.

SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Arrowhead Research Corp. To Contact Brower Piven Before The December 9, 2014 Lead Plaintiff Deadline In Class Action Lawsuit

SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Arrowhead Research Corp. To Contact Brower Piven Before The December 9, 2014 Lead Plaintiff Deadline In Class Action Lawsuit

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Central District of California on...

5 Stocks Under $10 Set to Soar

5 Stocks Under $10 Set to Soar

These under-$10 stocks look ready to trade higher from current levels.

Insider Trading Alert - CSX, IBKR And ARWR Traded By Insiders

Insider Trading Alert - CSX, IBKR And ARWR Traded By Insiders

Stocks with insider trader activity include CSX, IBKR and ARWR

Arrowhead Research (ARWR) Highlighted As Today's Perilous Reversal Stock

Arrowhead Research (ARWR) Highlighted As Today's Perilous Reversal Stock

Trade-Ideas LLC identified Arrowhead Research (ARWR) as a "perilous reversal" (up big yesterday but down big today) candidate

Trade-Ideas: Arrowhead Research (ARWR) Is Today's Post-Market Leader Stock

Trade-Ideas: Arrowhead Research (ARWR) Is Today's Post-Market Leader Stock

Trade-Ideas LLC identified Arrowhead Research (ARWR) as a post-market leader candidate

SHAREHOLDER ALERT: Class Action Lawsuit Against Arrowhead Research Corporation Filed By Glancy Binkow & Goldberg LLP

SHAREHOLDER ALERT: Class Action Lawsuit Against Arrowhead Research Corporation Filed By Glancy Binkow & Goldberg LLP

Glancy Binkow & Goldberg LLP, representing investors of Arrowhead Research Corporation (“Arrowhead” or the “Company”) (NASDAQ:ARWR), has filed a class action lawsuit in the United States...

Arrowhead Research Shareholder Alert: Former SEC Attorney Willie Briscoe And Powers Taylor Investigate Possible Breaches Of Fiduciary Duty By Officers And Directors

Arrowhead Research Shareholder Alert: Former SEC Attorney Willie Briscoe And Powers Taylor Investigate Possible Breaches Of Fiduciary Duty By Officers And Directors

Former United States Securities and Exchange Commission attorney Willie Briscoe, founder of The Briscoe Law Firm, PLLC, and the securities litigation firm of Powers Taylor LLP announce that a federal class action...

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors Of Class Action Against Arrowhead Research Corp. And Its Board Of Directors And A Lead Plaintiff Deadline Of December 9, 2014

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors Of Class Action Against Arrowhead Research Corp. And Its Board Of Directors And A Lead Plaintiff Deadline Of December 9, 2014

Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the Central District of California on behalf of investors who purchased Arrowhead Research Corp.

Biotech Stock Mailbag: Keryx, Puma, Gilead, Arrowhead and Hate Mail Galore!

Biotech Stock Mailbag: Keryx, Puma, Gilead, Arrowhead and Hate Mail Galore!

Biotech columnist Adam Feuerstein answers readers' questions about health care.

Trade-Ideas: Arrowhead Research (ARWR) Is Today's "Dead Cat Bounce" Stock

Trade-Ideas: Arrowhead Research (ARWR) Is Today's "Dead Cat Bounce" Stock

Trade-Ideas LLC identified Arrowhead Research (ARWR) as a "dead cat bounce" (down big yesterday but up big today) candidate

Arrowhead Issues Open Letter To Shareholders

Arrowhead Issues Open Letter To Shareholders

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today issued the following open letter to shareholders from President and CEO, Christopher Anzalone, Ph.

'Fast Money' Recap: Relief About the Stock Market Rally

'Fast Money' Recap: Relief About the Stock Market Rally

The trading panel discussed where they are putting their money after the change in market direction.

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Arrowhead Research Corp. - ARWR

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Arrowhead Research Corp. - ARWR

The Rosen Law Firm announces that it is investigating potential securities claims against Arrowhead Research Corp.

Blame Arrowhead Management Entirely for Today's Epic Collapse

Blame Arrowhead Management Entirely for Today's Epic Collapse

CEOs of early stage biotech companies like Arrowhead cannot deliver nasty surprises to Wall Street, yet some inexplicable reason, Anzalone totally botched the job.

3 Stocks Pushing The Drugs Industry Lower

3 Stocks Pushing The Drugs Industry Lower

TheStreet highlights 3 stocks pushing the drugs industry lower today.

Arrowhead Research Sinks on Disappointing Hepatitis B Drug Data

Arrowhead Research Sinks on Disappointing Hepatitis B Drug Data

In an ongoing phase II study, ARC-520 dosed at 2 mg/kg induced a 0.3 log reduction in HBsAG, a measure of the presence of hepatitis B virus in the body.

Arrowhead To Present ARC-520 Phase 2a Data In Late-Breaking Session At AASLD Liver Meeting® 2014

Arrowhead To Present ARC-520 Phase 2a Data In Late-Breaking Session At AASLD Liver Meeting® 2014

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that data from the ongoing Phase 2a study of ARC-520, its RNAi therapeutic candidate for...

Arrowhead To Present At 10th Annual Meeting Of The Oligonucleotide Therapeutics Society

Arrowhead To Present At 10th Annual Meeting Of The Oligonucleotide Therapeutics Society

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that the Company is presenting at the 10 th Annual Meeting of the Oligonucleotide...

Notable Two Hundred Day Moving Average Cross - ARWR

Notable Two Hundred Day Moving Average Cross - ARWR

In trading on Wednesday, shares of Arrowhead Research Corp crossed below their 200 day moving average of $14.52, changing hands as low as $13.61 per share. Arrowhead Research Corp shares are currently trading off about 4.9% on the day.

Arrowhead Expands Management Team With Appointment Of Susan Boynton As Vice President Global Regulatory Affairs

Arrowhead Expands Management Team With Appointment Of Susan Boynton As Vice President Global Regulatory Affairs

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that Susan Boynton has been appointed Vice President, Global Regulatory Affairs.

Arrowhead To Present At BioCentury’s NewsMakers In The Biotech Industry Conference

Arrowhead To Present At BioCentury’s NewsMakers In The Biotech Industry Conference

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that Bruce Given, M.

3 Biotech Breakout Charts That Could See More Upside Next Week

3 Biotech Breakout Charts That Could See More Upside Next Week

three four to watch for more upside.

Strong On High Volume: Arrowhead Research (ARWR)

Strong On High Volume: Arrowhead Research (ARWR)

Trade-Ideas LLC identified Arrowhead Research (ARWR) as a strong on high relative volume candidate

TheStreet Quant Rating: C+ (Hold)